Alnylam Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Alnylam Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.4%
Buyback Yield
| Total Shareholder Yield | -0.4% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak
Oct 31Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Aug 01
We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet
May 01Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Mar 21Alnylam: Waiting For Regulatory Updates In March
Feb 13Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment?
Jan 17What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You
Dec 16Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Oct 27Alnylam: HELIOS-B Success Priced In Already
Aug 30RNAi: Winning In The Clinic, Now For The Market
Jun 25Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
Jun 03Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ALNY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALNY's dividend payments have been increasing.
Dividend Yield vs Market
| Alnylam Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ALNY) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (ALNY) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ALNY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALNY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ALNY's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALNY has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 04:49 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alnylam Pharmaceuticals, Inc. is covered by 62 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Emily Bodnar | Berenberg |
| null null | BMO Capital Markets Equity Research |